Globus Medical Inc. Class A Common Stock vs iShares US Power Infrastructure ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while iShares US Power Infrastructure ETF trades at $24.99 (market cap $448.01M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 22.9× iShares US Power Infrastructure ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, iShares US Power Infrastructure ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and iShares US Power Infrastructure ETF for 19 Days on average.
| GMED | POWR | |
|---|---|---|
Market Cap | $10.25B | $448.01M |
Volume | 1,108,124 | 115,109 |
Sector | Health | Sector/Thematic |
52-Week High | $96.82 | $28.22 |
52-Week Low | $58.33 | $23.20 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $9.76B | — |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
POWR trades at $25.68, up 0.75% with a bullish technical signal from moving averages. The company reported $256.66M revenue in 2014 but posted a net loss of -$6.99M, with negative EBITDA of -$952K. Cash flow trends show volatility, with 2014 net cash flow at -$17.14M. The stock faces fundamental challenges despite technical strength, with debt-to-asset ratio at 7.09 indicating high leverage.
The outlook remains mixed with technical indicators supporting near-term upside, but fundamental weaknesses in profitability and cash flow generation pose significant risks. Investment opportunity exists if operational improvements materialize, while current financial metrics suggest caution for value-oriented investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →iShares U.S. Power Infrastructure ETF seeks exposure to U.S. companies involved in power infrastructure. Its holdings may include electric utilities, transmission and distribution businesses, and electrical equipment providers.
Read more on POWR →